Haggart Ryan, Polter Elizabeth, Ross Michael, Kohli Nidhi, Konety Badrinath R, Mitteldorf Darryl, West William, Rosser B R Simon
Department of Urology, University of Minnesota, Minneapolis, MN, USA.
Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Sex Med. 2021 Dec;9(6):100439. doi: 10.1016/j.esxm.2021.100439. Epub 2021 Oct 8.
Studies have demonstrated worse health related quality of life (HRQOL) outcomes in gay and bisexual men (GBM) following prostate cancer treatment compared to heterosexual men potentially due to differences in comorbidity burden.
To establish the prevalence of comorbidities and their association with HRQOL metrics in GBM following prostate cancer treatment.
We evaluated HRQOL and prevalence of comorbidities in 193 GBM from the United States and Canada in a cross-sectional, online survey: the Masked for Review. HRQOL was measured with the Expanded Prostate Cancer Index Composite (EPIC) and the 12-Item Short Form Health Survey (SF-12).
Our outcomes included comorbidity prevalence, mean differences for HRQOL scores by comorbidity status, and mean differences for HRQOL by comorbidity count.
GBM were found to have a higher prevalence of blood vessel disease and mental health disorders but lower prevalence of obesity and type 2 diabetes when compared to published data in general prostate cancer populations. Statistically significant reductions in HRQOL metrics were associated with mental health diagnoses, diabetes, and obesity. Increased number of comorbidities was also associated with reductions in HRQOL metrics in nearly all categories.
These results suggest that the worse QOL outcomes in GBM following prostate cancer treatment may be due to differences in comorbidity burden. This study is the first to evaluate the relationship between comorbidities and HRQOL outcomes in GBM. Limitations of this study include a small sample size and cross-sectional study design. If confirmed in larger, longitudinal, clinically confirmed studies, these findings indicate a need to intervene on and consider comorbidities in GBM diagnosed with prostate cancer. Haggart R, Polter E, Ross M, et al. Comorbidity Prevalence and Impact on Quality of Life in Gay and Bisexual Men Following Prostate Cancer Treatment. Sex Med 2021;9:100439.
研究表明，与异性恋男性相比，同性恋和双性恋男性（GBM）在接受前列腺癌治疗后的健康相关生活质量（HRQOL）结果更差，这可能是由于合并症负担的差异所致。
确定前列腺癌治疗后GBM中合并症的患病率及其与HRQOL指标的关联。
我们通过一项横断面在线调查“Masked for Review”，对来自美国和加拿大的193名GBM的HRQOL和合并症患病率进行了评估。HRQOL采用扩展前列腺癌指数综合量表（EPIC）和12项简短健康调查量表（SF-12）进行测量。
我们的观察指标包括合并症患病率、按合并症状态划分的HRQOL评分均值差异以及按合并症数量划分的HRQOL均值差异。
与一般前列腺癌人群的已发表数据相比，GBM被发现血管疾病和精神健康障碍的患病率较高，但肥胖和2型糖尿病的患病率较低。HRQOL指标的统计学显著降低与精神健康诊断、糖尿病和肥胖有关。合并症数量增加也与几乎所有类别中HRQOL指标的降低有关。
这些结果表明，前列腺癌治疗后GBM的生活质量较差可能是由于合并症负担的差异。本研究是首次评估GBM中合并症与HRQOL结果之间的关系。本研究的局限性包括样本量小和横断面研究设计。如果在更大规模的纵向临床确诊研究中得到证实，这些发现表明需要对诊断为前列腺癌的GBM中的合并症进行干预并加以考虑。哈格特R、波特E、罗斯M等。前列腺癌治疗后同性恋和双性恋男性的合并症患病率及其对生活质量的影响。性医学2021；9：100439。
